Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.25 USD | 0.00% | -3.11% | -21.56% |
30/05 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
30/05 | Bristol Myers: FDA approval for Breyanzi | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.56% | 8.16TCr | |
+39.82% | 73TCr | |
+31.34% | 59TCr | |
-7.31% | 35TCr | |
+14.23% | 32TCr | |
+0.86% | 27TCr | |
+13.47% | 24TCr | |
-6.63% | 20TCr | |
+7.49% | 20TCr | |
+4.51% | 16TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60